SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma - Quaterly Results

02 May 2024 Evaluate
The company witnessed a 14.22% growth in the revenue at Rs. 1638.17 millions for the quarter ended March 2024 as compared to Rs. 1434.19 millions during the year-ago period.The Net Loss for the quarter ended March 2024 is Rs. -114.61 millions as compared to Net Profit of Rs. 61.05 millions of corresponding quarter ended March 2023Operating profit surged to 336.13 millions from the corresponding previous quarter of 173.90 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 1638.17 1434.19 14.22 6054.60 5983.40 1.19 6054.60 5983.40 1.19
Other Income 84.64 64.79 30.64 335.01 507.66 -34.01 335.01 507.66 -34.01
PBIDT 336.13 173.90 93.29 1406.68 1409.21 -0.18 1406.68 1409.21 -0.18
Interest 15.31 49.73 -69.21 58.06 100.56 -42.26 58.06 100.56 -42.26
PBDT -90.04 124.17 -172.51 937.76 1308.65 -28.34 937.76 1308.65 -28.34
Depreciation 62.29 39.74 56.74 235.19 151.73 55.01 235.19 151.73 55.01
PBT -152.33 84.43 -280.42 702.57 1156.92 -39.27 702.57 1156.92 -39.27
TAX -37.72 23.38 -261.33 196.13 302.14 -35.09 196.13 302.14 -35.09
Deferred Tax -97.62 -24.68 295.54 -75.49 -42.10 79.31 -75.49 -42.10 79.31
PAT -114.61 61.05 -287.73 506.44 854.78 -40.75 506.44 854.78 -40.75
Equity 104.69 104.15 0.52 104.69 104.15 0.52 104.69 104.15 0.52
PBIDTM(%) 20.52 12.13 69.22 23.23 23.55 -1.35 23.23 23.55 -1.35

Bliss GVS Pharma Share Price

258.35 -0.95 (-0.37%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×